Health

Drug discovery technology developer Standigm added $10m to the cash it raised from SK Chemicals last week while Six FinTech Ventures helped fintech software provider Toqio secure $9.4m.

Swisscom and Hitachi-backed genomic data technology provider Sophia has filed to go public following some $250m in venture funding.

Mitsui and Nan Fung could exit the rare disease drug developer, which is set to float on the Nasdaq Global Select Market having set a $100m placeholder target.

The venture firm is working on a new vehicle which could be larger in size than its Sega Sammy and Septeni-backed second fund.

Eli Lilly has agreed to make an equity investment in Mina Therapeutics after approving a research collaboration with the saRNA drug developer earlier this year.

On-demand logistics provider Pickupp hiked its overall funding to $15m while SK Chemicals added to the $67m already raised by drug discovery technology producer Standigm.

UC Berkeley’s cell therapy developer has filed for an initial public offering.

AbbVie, Novartis, Corteva and Heritage Medical Systems will have an opportunity to exit the cell therapy developer through an initial public offering.

Sirnaomics, which counts Walvax Bio, China Resources Group and Charoen Pokphand Group as existing investors, has raised series E funding to advance its drug development activities.

The China-based ride hailing service company debuted in an upsized $4.44bn IPO, giving potential exits to several corporate backers that are among some of its largest external shareholders.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.